Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Abstract

Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• Délégation Paris 7 FR
• Université Paris Cité FR
• Harvard University US
• Assistance Publique – Hôpitaux de Paris FR
• University of Maryland, Baltimore US
• Inserm FR
• Lung Institute US
• Montreal Heart Institute CA
• Hôpital Bichat-Claude-Bernard FR
• Emory University US
• Université de Montréal CA
• Amarin (United States) US
• Baylor College of Medicine US
• Houston Methodist US
• Royal Brompton Hospital GB

Related Publications